Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Patritumab Deruxtecan in Gastrointestinal Cancers
2024-512442-41-00Phase 2Authorised
- Sponsor
- Merck & Co.
- Start
- Dec 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 15
01
Overview
Phase 2, open-label, single-arm trial of patritumab deruxtecan in colorectal cancer (CRC), biliary cancer, hepatocellular carcinoma (HCC) and 1 more, sponsored by Merck & Co. Primary endpoints: Number of Participants Experiencing Dose-Limiting Toxicity (DLT) (Dose-Escalation Phase), Number of Participants with One or More Adverse Events (AEs) and 2 more. Planned start Dec 2024; status: authorised.
02
Drugs
patritumab deruxtecan
03
Conditions
colorectal cancer (CRC)biliary cancerhepatocellular carcinoma (HCC)esophagogastric junction cancer
Beyond the preview
Go deeper on 2024-512442-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512442-41-00.